The Biden administration is proposing a new rule to expand Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound.
Current coverage is limited due to outdated legislation that excludes weight loss drugs, reflecting past views that obesity was cosmetic rather than a disease.
Professor Rachel Sachs highlighted that the exclusion stems from a time when weight loss drugs were less effective and obesity wasn't recognized as a medical condition.
The proposed rule aims to end this exclusion, providing broader access to these essential medications for individuals struggling with obesity.
Collection
[
|
...
]